BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11460470)

  • 1. Fibrinogen Longmont. A heterozygous abnormal fibrinogen with B beta Arg-166 to Cys substitution associated with defective fibrin polymerization.
    Lounes KC; Lefkowitz JB; Coates AI; Hantgan RR; Henschen-Edman A; Lord ST
    Ann N Y Acad Sci; 2001; 936():129-32. PubMed ID: 11460470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg-->Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers.
    Lounes KC; Lefkowitz JB; Henschen-Edman AH; Coates AI; Hantgan RR; Lord ST
    Blood; 2001 Aug; 98(3):661-6. PubMed ID: 11468164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen Matsumoto V: a variant with Aalpha19 Arg-->Gly (AGG-->GGG). Comparison between fibrin polymerization stimulated by thrombin or reptilase and fibrin monomer polymerization.
    Tanaka H; Terasawa F; Ito T; Tokunaga S; Ishida F; Kitano K; Kiyosawa K; Okumura N
    Thromb Haemost; 2001 Jan; 85(1):108-13. PubMed ID: 11204560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
    Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
    Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen Matsumoto III: a variant with gamma275 Arg-->Cys (CGC-->TGC)--comparison of fibrin polymerization properties with those of Matsumoto I (gamma364 Asp-->His) and Matsumoto II (gamma308 Asn-->Lys).
    Terasawa F; Okumura N; Higuchi Y; Ishikawa S; Tozuka M; Ishida F; Kitano K; Katsuyama T
    Thromb Haemost; 1999 May; 81(5):763-6. PubMed ID: 10365751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal binding of calcium to five fibrinogen variants with mutations in the carboxy terminal part of the gamma-chain.
    Furlan M; Stucki B; Steinmann C; Jungo M; Lämmle B
    Thromb Haemost; 1996 Sep; 76(3):377-83. PubMed ID: 8883274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen Bastia (gamma 318 Asp-->Tyr) a novel abnormal fibrinogen characterized by defective fibrin polymerization.
    Lounes KC; Soria C; Valognes A; Turchini MF; Soria J; Koopman J
    Thromb Haemost; 1999 Dec; 82(6):1639-43. PubMed ID: 10613648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Matsumoto I: a gamma 364 Asp-->His (GAT-->CAT) substitution associated with defective fibrin polymerization.
    Okumura N; Furihata K; Terasawa F; Nakagoshi R; Ueno I; Katsuyama T
    Thromb Haemost; 1996 Jun; 75(6):887-91. PubMed ID: 8822581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The polymerization of fibrin prepared from fibrinogen Haifa (gamma 275Arg----His).
    Siebenlist KR; Mosesson MW; Di Orio JP; Tavori S; Tatarsky I; Rimon A
    Thromb Haemost; 1989 Nov; 62(3):875-9. PubMed ID: 2512677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Milano V: a congenital dysfibrinogenaemia with a gamma 275 Arg-->Cys substitution.
    Steinmann C; Bögli C; Jungo M; Lämmle B; Heinemann G; Wermuth B; Redaelli R; Baudo F; Furlan M
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):463-71. PubMed ID: 7841300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen anomalies and disease. A clinical update.
    Galanakis DK
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1171-87. PubMed ID: 1400080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal plasmic cleavage of the gamma-chain variant of "fibrinogen Saga" with an Arg-275 to His substitution.
    Yamazumi K; Terukina S; Onohara S; Matsuda M
    Thromb Haemost; 1988 Dec; 60(3):476-80. PubMed ID: 2976995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygous abnormal fibrinogen Osaka III with the replacement of gamma arginine-275 by histidine has an apparently higher molecular weight gamma-chain variant.
    Yoshida N; Imaoka S; Hirata H; Matsuda M; Asakura S
    Thromb Haemost; 1992 Nov; 68(5):534-8. PubMed ID: 1455400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser-->Cys substitution associated with thrombosis.
    Marchi R; Lundberg U; Grimbergen J; Koopman J; Torres A; de Bosch NB; Haverkate F; Arocha Piñango CL
    Thromb Haemost; 2000 Aug; 84(2):263-70. PubMed ID: 10959699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (gamma 275 Arg-->Cys).
    Mosesson MW; Siebenlist KR; DiOrio JP; Matsuda M; Hainfeld JF; Wall JS
    J Clin Invest; 1995 Aug; 96(2):1053-8. PubMed ID: 7635941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator.
    Maekawa H; Yamazumi K; Muramatsu S; Kaneko M; Hirata H; Takahashi N; Arocha-Piñango CL; Rodriguez S; Nagy H; Perez-Requejo JL
    J Clin Invest; 1992 Jul; 90(1):67-76. PubMed ID: 1634621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new substitution, gamma 358 Ser-->Cys, in fibrinogen Milano VII causes defective fibrin polymerization.
    Steinmann C; Bögli C; Jungo M; Lämmle B; Heinemann G; Wermuth B; Redaelli R; Baudo F; Furlan M
    Blood; 1994 Sep; 84(6):1874-80. PubMed ID: 8080993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An engineered fibrinogen variant AαQ328,366P does not polymerise normally, but retains the ability to form α cross-links.
    Park R; Ping L; Song J; Seo JY; Choi TY; Choi JR; Gorkun OV; Lord ST
    Thromb Haemost; 2013 Feb; 109(2):199-206. PubMed ID: 23224113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.